Celltrion-Hospira's Inflectra wins EU nod

The European Commission approved Hospira and Celltrion's Inflectra, a biosimilar version of rheumatoid arthritis drug Remicade from Johnson & Johnson and Merck & Co. The approval makes Inflectra the first biosimilar monoclonal antibody drug cleared in the European Union.

View Full Article in:

Wall Street Journal (tiered subscription model), The · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX